FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

(2017) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

(2017) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Imminent fracture risk

(2017) C. Roux et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

(2016) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

(2016) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Imminent risk of fracture after fracture

(2016) H. Johansson et al.   OSTEOPOROSIS INTERNATIONAL

Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis

(2015) Christian Graeff et al.   BONE

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

(2015) S. Ferrari et al.   OSTEOPOROSIS INTERNATIONAL

Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody

(2014) Xiaodong Li et al.   ENDOCRINOLOGY

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone mineralization: from tissue to crystal in normal and pathological contexts

(2012) Y. Bala et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Quantifying the material and structural determinants of bone strength

(2009) Mary L. Bouxsein et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Hip Fracture Patients at Risk of Second Hip Fracture: A Nationwide Population-Based Cohort Study of 169,145 Cases During 1977–2001

(2009) Jesper Ryg et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical subsequent fractures cluster in time after first fractures

(2008) T A C M van Geel et al.   ANNALS OF THE RHEUMATIC DISEASES

Subsequent Fracture in Nursing Home Residents with a Hip Fracture: A Competing Risks Approach

(2008) Sarah D. Berry et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents

(2008) K. W. Lyles et al.   OSTEOPOROSIS INTERNATIONAL

Bone quality: the material and structural basis of bone strength

(2007) Ego Seeman   JOURNAL OF BONE AND MINERAL METABOLISM